Radiotherapy by Sonic Hedgehog Pathway Inhibitors in Basal Cell Carcinoma

计划入组 82 人 · 首次发布于 2022 年 9 月 30 日

PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy

计划入组 138 人 · 首次发布于 2017 年 4 月 28 日

Safety and Efficacy of ASN-002 Combined With a Hedgehog Pathway Inhibitor

计划入组 21 人 · 首次发布于 2020 年 6 月 4 日

ETS-2400

Vismodegib(Erivedge)

C₁₉H₁₄Cl₂N₂O₃S · Rx

Hedgehog inhibitors (Abraxis)

Pathway Therapeutics, Inc.

United States

Erasca

United States

Eledon Pharmaceuticals

United States

Cemiplimab Shows Promise in Advanced Basal Cell Carcinoma After Hedgehog Inhibitor Failure

Advancements in Neuroplastogens, KRAS G12C Inhibitors, and Other Therapies Highlighted by Recent Deals and Clinical Readouts

Sol-Gel Discontinues SGT-210 Development for Darier Disease After Phase 1b Trial Fails to Show Efficacy